Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J8611 Methotrexate (jylamvo) Jylamvo 2.5mg Chemotherapy Antimetabolite Folic Acid Analog Yes 2023 Jun 10, 2024 In Use
C9252 Plerixafor Mozobil 1 mg Ancillary Therapy Immunostimulant Stem Cell Mobilizer No 2008 Jul 1, 2009 Dec 31, 2009 No Longer Used
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct 1, 2014 Dec 31, 2015 No Longer Used
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J0893 Decitabine (Sun Pharma) Decitabine 1mg Chemotherapy Antimetabolite Pyrimidine Analog No 2014 Dec 21, 2022 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No Apr 1, 2002 In Use
J9282 Mitomycin Intravesical Instillation Zusduri 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 2025 Jan 1, 2026 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
J9050 Carmustine Bicnu 100 mg Chemotherapy Alkylating Agent Nitrosourea No 1977 Jan 1, 1984 In Use
NA Dasatinib Sprycel 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J9289 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2mg Immunotherapy Checkpoint Inhibitor PD-1 No 2025 Jul 9, 2025 In Use
J9301 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Jan 1, 2015 In Use
J9302 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Jan 1, 2011 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
NA Sunitinib malate Sutent 37.5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
C9170 Tarlatamab-dlle, 1 mg IMDELLTRA 1mg Immunotherapy T Cell Receptor (TCR) DLL3, CD3 No 2024 Sep 11, 2024 Dec 17, 2024 No Longer Used
J2860 Siltuximab Sylvant 10 mg Immunotherapy Monoclonal Antibody IL-6 No 2014 Jan 1, 2016 In Use
J3130 Testosterone Enanthate Testosterone Enanthate 200 mg Hormonal Therapy Androgen No 1953 Jan 1, 1982 Jan 1, 2015 No Longer Used
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.